Arbutus Biopharma (ABUS) Assets Average (2016 - 2025)

Historic Assets Average for Arbutus Biopharma (ABUS) over the last 16 years, with Q3 2025 value amounting to $100.5 million.

  • Arbutus Biopharma's Assets Average fell 3311.56% to $100.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.5 million, marking a year-over-year decrease of 3311.56%. This contributed to the annual value of $138.1 million for FY2024, which is 1874.87% down from last year.
  • As of Q3 2025, Arbutus Biopharma's Assets Average stood at $100.5 million, which was down 3311.56% from $110.1 million recorded in Q2 2025.
  • Arbutus Biopharma's Assets Average's 5-year high stood at $226.4 million during Q2 2022, with a 5-year trough of $100.5 million in Q3 2025.
  • Its 5-year average for Assets Average is $162.9 million, with a median of $151.5 million in 2023.
  • Per our database at Business Quant, Arbutus Biopharma's Assets Average surged by 6075.54% in 2022 and then plummeted by 3311.56% in 2025.
  • Over the past 5 years, Arbutus Biopharma's Assets Average (Quarter) stood at $185.0 million in 2021, then increased by 7.87% to $199.6 million in 2022, then fell by 24.09% to $151.5 million in 2023, then decreased by 10.19% to $136.1 million in 2024, then fell by 26.15% to $100.5 million in 2025.
  • Its last three reported values are $100.5 million in Q3 2025, $110.1 million for Q2 2025, and $124.4 million during Q1 2025.